Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mori J Krantz

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
Pharmacotherapy|December 9, 2004
Angiotensin-converting enzyme inhibitors and stroke: blood pressure reduction is major determinant of riskMori J Krantz
Journal of Addictive Diseases|December 2, 2008
Heterogeneous impact of methadone on the QTc interval: what are the practical implications?Mori J Krantz
Annals of Internal Medicine|March 17, 2004
Blood pressure control in type 2 diabetes mellitusMori J Krantz
The American Journal of Cardiology|October 1, 2003
Angiotensin-converting enzyme inhibitors: optimal management of cardiovascular riskMori J Krantz
JAMA|April 8, 2004
Cardiovascular effects of ephedraMori J Krantz
The American Journal of Cardiology|July 3, 2025
Legends in Cardiology: Giant Sense of HumorMori J Krantz
Pharmacotherapy|June 29, 2006
Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?Mori J Krantz
Archives of Internal Medicine|November 15, 2006
QTc prolongation among hospitalized patients receiving methadoneJohn Schmittner, Mori J Krantz
Journal of the American College of Cardiology|June 11, 2013
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51)Mori J Krantz, Sanjay Kaul
The American Journal of Medicine|June 22, 2013
The replyVikas Aggarwal, Mori J Krantz
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
Pharmacotherapy|December 9, 2004
Angiotensin-converting enzyme inhibitors and stroke: blood pressure reduction is major determinant of riskMori J Krantz
Journal of Addictive Diseases|December 2, 2008
Heterogeneous impact of methadone on the QTc interval: what are the practical implications?Mori J Krantz
Annals of Internal Medicine|March 17, 2004
Blood pressure control in type 2 diabetes mellitusMori J Krantz
The American Journal of Cardiology|October 1, 2003
Angiotensin-converting enzyme inhibitors: optimal management of cardiovascular riskMori J Krantz
JAMA|April 8, 2004
Cardiovascular effects of ephedraMori J Krantz
The American Journal of Cardiology|July 3, 2025
Legends in Cardiology: Giant Sense of HumorMori J Krantz
Pharmacotherapy|June 29, 2006
Implications of thiazolidinedione use and cardiovascular risk: is it all about the sugar?Mori J Krantz
Archives of Internal Medicine|November 15, 2006
QTc prolongation among hospitalized patients receiving methadoneJohn Schmittner, Mori J Krantz
Journal of the American College of Cardiology|June 11, 2013
The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51)Mori J Krantz, Sanjay Kaul
The American Journal of Medicine|June 22, 2013
The replyVikas Aggarwal, Mori J Krantz
Pageof 17